Jong Hee Shin

Prof. Jong Hee Shin

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
WLWee Gyo Lee
Wee Gyo Lee
JSJong Hee Shin
Jong Hee Shin
YUYoung Uh
Young Uh
MKMin Gu Kang
Min Gu Kang
SKSoo Hyun Kim
Soo Hyun Kim
HJHee-Chang Jang
Hee-Chang Jang
Candida auris is a newly described species whose clinical significance is not clear. Here, we describe the first three cases of nosocomial fungemia caused by C. auris , which confirms that it is a causative agent of bloodstream infections. All three patients presented persistent fungemia for 10 to 31 days. The isolates obtained from the three patients were misidentified as Candida haemulonii and Rhodotorula glutinis by the Vitek 2 and the API 20C systems, respectively. C. auris was confirmed by sequence analysis of the internal transcribed spacer region and D1/D2 regions of the 26S ribosomal DNA of the rRNA gene. The MIC ranges of amphotericin B (AMB), fluconazole (FLU), itraconazole, and voriconazole were 0.5 to 1, 2 to 128, 0.125 to 2, and 0.06 to 1 μg/ml, respectively. All isolates were susceptible to caspofungin (MIC = 0.06 μg/ml) and micafungin (MIC = 0.03 μg/ml). One patient developed breakthrough fungemia while receiving FLU therapy, and two patients who received FLU therapy followed by AMB showed therapeutic failure and fatal outcomes. Our cases show that C. auris fungemia can be persistent, despite FLU or AMB therapy, which emphasizes the importance of accurately identifying this species.

1 April 2002 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
JSJong Hee Shin
Jong Hee Shin
SKSeung-Jung Kee
Seung-Jung Kee
MSMyung Geun Shin
Myung Geun Shin
SKSoo Hyun Kim
Soo Hyun Kim
DSDong Hyeon Shin
Dong Hyeon Shin
DRDong Wook Ryang
Dong Wook Ryang
Biofilm production has been implicated as a potential virulence factor of some Candida species responsible for catheter-related fungemia in patients receiving parenteral nutrition. We therefore compared clinical bloodstream isolates representing seven different Candida species to each other and to those from other anatomical sites for the capacity to form biofilms in glucose-containing medium. Potential associations between the capacity to form biofilms and the clinical characteristics of fungemia were also analyzed. Isolates included the following from nonneutropenic patients: 101 bloodstream isolates (35 C. parapsilosis , 30 C. albicans , 18 C. tropicalis , 8 C. glabrata , and 10 other Candida species isolates) and 259 clinical isolates from other body sites (116 C. albicans , 53 C. glabrata , 43 C. tropicalis , 17 C. parapsilosis , and 30 other Candida species isolates). Organisms were grown in Sabouraud dextrose broth (SDB) containing a final concentration of 8% glucose to induce biofilm formation, as published previously. Biofilm production was determined by both visual and spectrophotometric methods. In this medium, biofilm production by C. albicans isolates was significantly less frequent (8%) than that by non- C. albicans Candida species (61%; P < 0.0001). The overall proportion of non- C. albicans Candida species isolates from the blood that produced biofilms was significantly higher than that of non- C. albicans Candida isolates obtained from other sites (79% versus 52%; P = 0.0001). Bloodstream isolates of C. parapsilosis alone were significantly more likely to be biofilm positive than were C. parapsilosis isolates from other sites (86% versus 47%; P = 0.0032). Non- C. albicans Candida species, including C. parapsilosis , were more likely to be biofilm positive if isolates were derived from patients whose candidemia was central venous catheter (CVC) related (95%; P < 0.0001) and was associated with the use of total parenteral nutrition (TPN) (94%; P < 0.005). These data suggest that the capacity of Candida species isolates to produce biofilms in vitro in glucose-containing SDB may be a reflection of the pathogenic potential of these isolates to cause CVC-related fungemia in patients receiving TPN.

15 March 2009 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MKMi‐Na Kim
Mi‐Na Kim
JSJong Hee Shin
Jong Hee Shin
HSHeungsup Sung
Heungsup Sung
KLKyungwon Lee
Kyungwon Lee
EKEui‐Chong Kim
Eui‐Chong Kim
DRDong Wook Ryang
Dong Wook Ryang
Background.Candida haemulonii, a yeast species that often exhibits antifungal resistance, rarely causes human infection. During 2004–2006, unusual ye

8 June 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JRJeanne Ropars
Jeanne Ropars
CMCorinne Maufrais
Corinne Maufrais
DDDorothée Diogo
Dorothée Diogo
MMMarina Marcet-Hoiben
Marina Marcet-Hoiben
APAurélie Perin
Aurélie Perin
CDChristophe D’eNfert
Christophe D’eNfert
Elucidating population structure and levels of genetic diversity and recombination is necessary to understand the evolution and adaptation of species.Candida albicansis the second most frequent agent of human fungal infections worldwide, causing high-mortality rates. Here we present the genomic sequences of 182 C.albicansisolates collected worldwide, including commensal isolates, as well as ones responsible for superficial and invasive infections, constituting the largest dataset to date for this major fungal pathogen. Although,C.albicansshows a predominantly clonal population structure, we find evidence of gene flow between previously known and newly identified genetic clusters, supporting the occurrence of (para)sexuality in nature. A highly clonal lineage, which experimentally shows reduced fitness, has undergone pseudogenization in genes required for virulence and morphogenesis, which may explain its niche restriction.Candida albicansthus takes advantage of both clonality and gene flow to diversify.

1 April 2019 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
YKYong Jun Kwon
Yong Jun Kwon
JSJong Hee Shin
Jong Hee Shin
SBSeung A Byun
Seung A Byun
MCMin Ji Choi
Min Ji Choi
Eun Jeong WonEun Jeong Won
Eun Jeong Won
MSMyung Geun Shin
Myung Geun Shin
Candida auris is an emerging worldwide fungal pathogen. Over the past 20 years, 61 patient isolates of C. auris (4 blood and 57 ear) have been obtained from 13 hospitals in Korea. Here, we reanalyzed those molecularly identified isolates using two matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) systems, including Biotyper and Vitek MS, followed by antifungal susceptibility testing, sequencing of the ERG11 gene, and genotyping. With a research-use-only (RUO) library, 83.6% and 93.4% of the isolates were correctly identified by Biotyper and Vitek MS, respectively. Using an in vitro diagnostic (IVD) library of Vitek MS, 96.7% of the isolates were correctly identified. Fluconazole-resistant isolates made up 62.3% of the isolates, while echinocanidin- or multidrug-resistant isolates were not found. Excellent essential (within two dilutions, 96.7%) and categorical agreements (93.4%) between the Clinical and Laboratory Standards Institute (CLSI) and Vitek 2 (AST-YS07 card) methods were observed for fluconazole. Sequencing ERG11 for all 61 isolates revealed that only 3 fluconazole-resistant isolates showed Erg11p amino-acid substitution K143R. All 61 isolates showed identical multilocus sequence typing (MLST). Pulsed-field gel electrophoresis (PFGE) analyses revealed that both blood and ear isolates had the same or similar patterns. These results show that MALDI-TOF MS and Vitek 2 antifungal susceptibility systems can be reliable diagnostic tools for testing C. auris isolates from Korean hospitals. The Erg11p mutation was seldom found among Korean isolates of C. auris, and multidrug resistance was not found. Both MLST and PFGE analyses suggest that these isolates are genetically similar.

1 August 2007 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
JSJong Hee Shin
Jong Hee Shin
MCMyung Jong Chae
Myung Jong Chae
JSJeong Won Song
Jeong Won Song
SJSook-In Jung
Sook-In Jung
DCDuck Cho
Duck Cho
DRDong Wook Ryang
Dong Wook Ryang
We examined the changes in genotypes and azole susceptibilities among sequential bloodstream isolates of Candida glabrata during the course of fungemia and the relationship of these changes to antifungal therapy. Forty-one isolates were obtained from 15 patients (9 patients who received antifungal therapy and 6 patients who did not) over periods of up to 36 days. The isolates were analyzed using pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) and tested for antifungal susceptibility to fluconazole, itraconazole, and voriconazole. PFGE typing consisted of electrophoretic karyotyping and restriction endonuclease analysis of genomic DNA by use of NotI (REAG-N). The 41 isolates yielded 23 different karyotypes and 11 different REAG-N patterns but only 3 MLST types. The sequential strains from each patient had identical or similar REAG-N patterns. However, they had two or three different karyotypes in 6 (40%) of 15 patients. The isolates from these six patients exhibited the same or similar azole susceptibilities, and five patients did not receive antifungal therapy. Development of acquired azole resistance in sequential isolates was detected for only one patient. For this patient, an isolate of the same genotype obtained after azole therapy showed three- or fourfold increases in the MICs of all three azole antifungals and exhibited increased expression of the CgCDR1 efflux pump. This study shows that karyotypic changes can develop rapidly among sequential bloodstream strains of C. glabrata from the same patient without antifungal therapy. In addition, we confirmed that C. glabrata could acquire azole resistance during the course of fungemia in association with azole therapy.